Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38.29 | 35.66 | 38.84 | 32.54 | 41.22 | 36.89 | 41.05 | 35.53 | 45.56 | 43.02 | 44.63 | 35.51 |
| Expenses | 29.19 | 28.47 | 28.99 | 23.26 | 29.79 | 28.07 | 30.19 | 26.58 | 32.45 | 35.59 | 30.38 | 29.48 |
| Operating Profit | 9.10 | 7.19 | 9.85 | 9.28 | 11.43 | 8.82 | 10.86 | 8.95 | 13.11 | 7.43 | 14.25 | 6.03 |
| OPM % | 23.77% | 20.16% | 25.36% | 28.52% | 27.73% | 23.91% | 26.46% | 25.19% | 28.78% | 17.27% | 31.93% | 16.98% |
| Other Income | 1.10 | 1.35 | 1.19 | 1.41 | 1.85 | 1.58 | 1.88 | 2.06 | 2.08 | 1.82 | 0.40 | 1.51 |
| Interest | 0.07 | 0.07 | 0.06 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 |
| Depreciation | 0.59 | 0.63 | 0.62 | 0.52 | 0.64 | 0.78 | 0.79 | 0.72 | 0.74 | 0.83 | 0.81 | 0.64 |
| Profit before tax | 9.54 | 7.84 | 10.36 | 10.06 | 12.52 | 9.51 | 11.84 | 10.18 | 14.34 | 8.30 | 13.71 | 6.77 |
| Tax % | 23.27% | 31.12% | 23.94% | 26.34% | 23.32% | 31.65% | 27.87% | 23.48% | 29.08% | 28.55% | 20.86% | 13.00% |
| Net Profit | 7.32 | 5.40 | 7.88 | 7.42 | 9.60 | 6.51 | 8.54 | 7.79 | 10.16 | 5.93 | 10.85 | 5.89 |
| EPS in Rs | 16.59 | 12.24 | 17.86 | 16.81 | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 94 | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 142 | 152 | 169 | 169 |
| Expenses | 77 | 84 | 91 | 98 | 99 | 89 | 97 | 106 | 109 | 111 | 125 | 128 |
| Operating Profit | 16 | 20 | 24 | 25 | 20 | 20 | 27 | 30 | 33 | 40 | 44 | 41 |
| OPM % | 18% | 19% | 21% | 20% | 17% | 18% | 22% | 22% | 23% | 27% | 26% | 24% |
| Other Income | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 7 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| Profit before tax | 17 | 20 | 25 | 27 | 21 | 22 | 30 | 33 | 35 | 44 | 47 | 43 |
| Tax % | 36% | 34% | 32% | 26% | 30% | 24% | 25% | 25% | 26% | 27% | 25% | |
| Net Profit | 11 | 14 | 17 | 20 | 15 | 16 | 22 | 25 | 26 | 32 | 35 | 33 |
| EPS in Rs | 23.19 | 29.06 | 37.50 | 43.14 | 32.40 | 35.95 | 48.59 | 55.76 | 58.87 | 72.64 | 78.72 | 74.39 |
| Dividend Payout % | 31% | 28% | 24% | 24% | 25% | 28% | 25% | 26% | 26% | 25% | 26% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 6% | 9% | 7% | 9% | ||
| Compounded Profit Growth | 13% | 18% | 15% | 10% | ||
| Stock Price CAGR | 10% | 14% | 10% | -15% | ||
| Return on Equity | 21% | 20% | 20% | 20% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
| Reserves | 29 | 36 | 50 | 57 | 73 | 75 | 94 | 113 | 118 | 141 | 167 | 193 |
| Borrowings | 7 | 5 | 6 | 0 | 7 | 3 | 5 | 7 | 3 | 0 | 4 | 2 |
| Other Liabilities | 21 | 12 | 16 | 16 | 18 | 21 | 17 | 18 | 16 | 19 | 19 | 26 |
| Total Liabilities | 61 | 58 | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
| Fixed Assets | 12 | 12 | 11 | 10 | 10 | 12 | 11 | 11 | 10 | 10 | 15 | 19 |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 40 | 46 |
| Investments | 0 | 1 | 2 | 5 | 5 | 4 | 7 | 8 | 11 | 17 | 21 | 27 |
| Other Assets | 49 | 45 | 64 | 62 | 87 | 88 | 103 | 123 | 119 | 136 | 120 | 132 |
| Total Assets | 61 | 58 | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 9 | 8 | 10 | 16 | 13 | 15 | 19 | 9 | 17 | 8 | 28 | 27 |
| Cash from Investing Activity | 1 | -0 | -10 | 1 | -11 | -3 | -19 | -1 | 3 | -1 | -17 | -19 |
| Cash from Financing Activity | 1 | -5 | 1 | -18 | -2 | -11 | -1 | -6 | -21 | -7 | -8 | -9 |
| Net Cash Flow | 11 | 2 | 1 | -1 | 0 | 1 | -0 | 3 | -1 | 0 | 3 | -2 |
| Free Cash Flow | 8 | 5 | 10 | 16 | 11 | 11 | 18 | 7 | 15 | 6 | 8 | 13 |
| CFO/OP | 88% | 82% | 85% | 103% | 80% | 104% | 127% | 62% | 83% | 49% | 102% | 88% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 23 | 32 | 40 | 68 | 55 | 47 | 45 | 45 | 50 | 50 | 53 |
| Inventory Days | 107 | 109 | 128 | 73 | 99 | 120 | 92 | 115 | 92 | 103 | 109 | 154 |
| Days Payable | 54 | 44 | 72 | 44 | 66 | 58 | 56 | 83 | 67 | 75 | 100 | 91 |
| Cash Conversion Cycle | 85 | 88 | 89 | 69 | 101 | 117 | 83 | 77 | 70 | 78 | 59 | 115 |
| Working Capital Days | -11 | 6 | 10 | 25 | 35 | 32 | 17 | 16 | 31 | 36 | 31 | 41 |
| ROCE % | 42% | 40% | 39% | 42% | 37% | 26% | 24% | 26% | 27% | 26% | 27% | 27% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 47.42% | 47.39% | 47.23% | 46.71% | 46.71% | 46.69% | 46.68% | 46.67% | 46.66% | 46.65% | 46.64% | 46.62% |
| FIIs | 1.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
| Public | 51.21% | 52.63% | 52.78% | 53.29% | 53.28% | 53.20% | 53.20% | 53.21% | 53.22% | 53.24% | 53.24% | 53.27% |
| No. of Shareholders | 5,872 | 6,021 | 6,316 | 6,419 | 6,628 | 6,901 | 6,987 | 6,712 | 6,855 | 7,163 | 6,999 | 7,103 |
Fundamentals
Market Cap₹ 403 Cr.
Current Price₹ 924
Stock P/E11.3
Book Value₹ 446
ROCE27.0 %
ROE20.2 %
Dividend Yield2.24 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)9%
Compounded Profit Growth (TTM)10%
Standalone figures.
Valuation
Market capRs 404 Cr
Enterprise valueRs 353 Cr
P/E (TTM)12.30x
Price to book2.05x
Price to sales2.39x
EV / EBITDA7.58x
EV / EBIT8.10x
EV / sales2.09x
Price to cash flow15.23x
Earnings yield8.13%
Dividend yield2.26%
P/E, 3-year average12.59x
P/B, 3-year average2.28x
P/E, 5-year average12.37x
P/B, 5-year average2.31x
Profitability
Operating margin (excl. other income)25.93%
Operating margin (incl. other income)29.68%
EBITDA margin27.64%
Pre-tax margin25.56%
Net profit margin19.46%
Net margin, latest quarter16.59%
ROE18.84%
ROCE25.04%
ROA16.54%
ROE, 3-year average19.51%
ROCE, 3-year average26.32%
ROA, 3-year average17.13%
ROE, 5-year average19.94%
ROCE, 5-year average26.44%
ROA, 5-year average17.13%
ROIC (approx.)22.24%
Tax rate25.32%
Other income / net worth3.22%
Growth
Sales growth (latest year)11.24%
Profit growth (latest year)8.36%
Sales CAGR, 3 years7.26%
Sales CAGR, 5 years9.08%
Profit CAGR, 3 years12.18%
Profit CAGR, 5 years16.06%
Sales growth QoQ-20.43%
Profit growth QoQ-45.71%
Sales growth YoY (latest quarter)-0.06%
Profit growth YoY (latest quarter)-24.39%
Per share
EPS (TTM)Rs 74.39
EPS (latest year)Rs 78.72
EPS (latest quarter)Rs 13.35
EPS, 3-year averageRs 70.08
EPS, 5-year averageRs 62.49
Book value per shareRs 446.47
Sales per shareRs 382.30
Cash flow per shareRs 60.09
Free cash flow per shareRs 29.46
Dividend per share (latest year)Rs 20.69
Dividend per share, 3-year averageRs 17.99
Dividend per share, 5-year averageRs 15.96
Dividends
Dividend payout26.28%
Dividend payout, 3-year average25.68%
Dividend payout, 5-year average25.51%
Efficiency
Asset turnover0.75x
Fixed asset turnover8.67x
Inventory turnover2.79x
Inventory days131 days
Debtor days53 days
Debtors turnover6.93x
Creditor days91 days
Cash conversion cycle115 days
Working capital days41 days
Leverage
Total debtRs 2 Cr
Cash and bankRs 53 Cr
Net debtRs -51 Cr
Debt to equity0.01x
Net debt / EBITDA-1.09x
Interest coverage89.00x
Owners' fund to total sources87.56%
Debt to assets1.11%
Cash flow
Cash from Operating Activity (latest year)Rs 27 Cr
Cash from Investing Activity (latest year)Rs -19 Cr
Cash from Financing Activity (latest year)Rs -9 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs 13 Cr
FCFE (approx.: FCF + change in debt)Rs 12 Cr
Cash from ops / profit, 5 years0.64x
Sales to cash flow6.36x
Statement figures
Net sales (TTM)Rs 169 Cr
Net sales (latest year)Rs 169 Cr
Sales (latest quarter)Rs 36 Cr
Operating profit excl. other income (latest year)Rs 44 Cr
Operating profit (latest quarter)Rs 6 Cr
Other income (TTM)Rs 6 Cr
EBITDA (TTM)Rs 47 Cr
PBDT (TTM)Rs 46 Cr
Profit before tax (TTM)Rs 43 Cr
Tax (latest year)Rs 12 Cr
Net profit (TTM)Rs 33 Cr
Net profit (latest year)Rs 35 Cr
Net profit (latest quarter)Rs 6 Cr
Depreciation (TTM)Rs 3 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 38 Cr
Total expenditure (latest year)Rs 125 Cr
Total income (latest year)Rs 175 Cr
Share capitalRs 4 Cr
ReservesRs 193 Cr
Shareholders' fundsRs 197 Cr
Total assetsRs 225 Cr
Net blockRs 19 Cr
Capital work in progressRs 46 Cr
InvestmentsRs 27 Cr
ReceivablesRs 24 Cr
InventoryRs 14 Cr
Other liabilitiesRs 26 Cr
Shares outstanding (crore)0.44
Ownership
Promoter holding46.62% (-0.05 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 12.3 is at the 27th percentile of its own 9.4-year range
(median 13.7, low 7.2, high 23.9).
P/B 2.05 is at the 4th percentile (median 2.65).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | JENBURPH | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -4.1% | -2.8% | -1.3 pts |
| 1 month | -12.7% | -6.8% | -5.9 pts |
| 3 years | +30.7% | +14.2% | +16.5 pts |
| 5 years | +90.3% | +27.9% | +62.4 pts |
Red flags
F-score 4 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹36 Cr -0.1% vs Jun 2025.
Net profit ₹6 Cr -24.4%.
Against our estimate for Jun 2026: sales -11.3%, profit -33.5% big miss. Our estimate for Sep 2026: sales Rs 48 Cr, profit Rs 9 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-08-28 | Dividend - Rs 20.70 Per Share |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd (JENBURPH) has a market capitalisation of Rs 403 Cr. at the 2026-10-01 close.
What is the P/E ratio of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd trades at a P/E of 11.3 on trailing twelve-month profit, at the 2026-10-01 close.
What were Jenburkt Pharmaceuticals Ltd's latest quarterly results?
In the Jun 2026 quarter, Jenburkt Pharmaceuticals Ltd sales was Rs 36 Cr (-0.1% vs Jun 2025) and net profit was Rs 6 Cr.
What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd?
The 52-week high is Rs 1,073.90 and the 52-week low is Rs 911.10.